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Lipid-mobilising factor (LMF) is produced by cachexia-inducing tumours and is involved in the degradation of adipose tissue, with
increased oxidation of the released fatty acids through an induction of uncoupling protein (UCP) expression. Since UCP-2 is thought
to be involved in the detoxification of free radicals if LMF induced UCP-2 expression in tumour cells, it might attenuate free radical
toxicity. As a model system we have used MAC13 tumour cells, which do not produce LMF. Addition of LMF caused a
concentration-dependent increase in UCP-2 expression, as determined by immunoblotting. This effect was attenuated by the b3
antagonist SR59230A, suggesting that it was mediated through a b3 adrenoreceptor. Co-incubation of LMF with MAC13 cells
reduced the growth-inhibitory effects of bleomycin, paraquat and hydrogen peroxide, known to be free radical generators, but not
chlorambucil, an alkylating agent. There was no effect of LMF alone on cellular proliferation. These results indicate that LMF
antagonises the antiproliferative effect of agents working through a free radical mechanism, and may partly explain the
unresponsiveness to the chemotherapy of cachexia-inducing tumours.
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Wasting of adipose tissue in cancer cachexia appears to be
mediated, at least in part, by a 43 kDa glycoprotein, lipid-
mobilising factor (LMF), secreted by cachexigenic tumours (Hirai
et al, 1998), which acts to directly stimulate lipolysis through a
cyclic AMP-mediated process. Lipid-mobilising factor was shown
to be homologous to the plasma protein zinc-a2-glycoprotein
(ZAG) (Todorov et al, 1998). In addition to stimulation of
triglyceride hydrolysis, LMF also increases oxidation of the
released fatty acids into carbon dioxide through increased
expression of uncoupling proteins (UCPs). Lipid-mobilising factor
induces increased expression of UCP-1, -2 and -3 in brown adipose
tissue (BAT), and UCP-2 in both skeletal muscle and liver (Bing
et al, 2002). UCP-1 channels protons across the inner mitochon-
drial membrane not linked to ATP production, and thus constitute
an energy sink. While UCP-1 is found only in BAT and has a
marked and strongly regulated uncoupling activity, UCP-2 is
found in most tissues, but the correlation between the expression
level of UCP-2 and the proton leak of the inner membrane is
somewhat controversial (Cadenas et al, 1999; Ricquier and
Bouillaud, 2000). A potential role of UCP-2 is in the detoxification
of superoxide radicals (O2) produced by one-electron reduction
of oxygen in the mitochondria. Thus, the tumour necrosis factor a
(TNF-a)-dependent increase in oxidant production by liver
mitochondria caused UCP-2 induction, and this may represent
an antioxidant defence mechanism (Lee et al, 1999). An increased
reactive oxygen species (ROS) formation was also observed in
hepatocytes prior to UCP-2 induction by lipid emulsion (Cortez-
Pinto et al, 1999).
An important question is whether there is any survival
advantage to tumours which produce catabolic factors such as
LMF. Most tumours use glucose rather than lipids as an energy
source due to the low oxygen tension, although release of
polyunsaturated fatty acids, such as linoleic or arachidonic acids,
may result in stimulation of tumour growth (Sauer and Dauchy,
1987). If LMF induced UCP-2 expression in the tumour, this may
be important in detoxifying free radicals, which are produced in
excess during the process of cachexia (Gomes-Marcondes and
Tisdale, 2002; Mantovani et al, 2002). Many anticancer drugs such
as adriamycin, bleomycin and mitomycin C exert their action
through generation of reactive oxygen radicals, and induction of
UCP-2 by LMF may protect tumour cells from their cytotoxic
action. These agents constitute one of the most important groups
of antitumour agents because they possess broad spectrum
activity.
To investigate this possibility, the effect of LMF on oxidant
damage induced by a range of agents was determined in a cell line
(MAC13) which does not produce LMF (Todorov et al, 1998), and
the mechanism of this effect was determined.
MATERIALS AND METHODS
Materials
Foetal calf serum (PCS) and RPMI 1640 tissue culture media were
purchased from Life Technologies (Paisley, UK). Rabbit polyclonal
antisera to mouse UCP-2 was purchased from Calbiochem through
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CN Biosciences UK (Nottingham, UK), while mouse monoclonal
antibody to human ZAG was from Santa Cruz Biotechnology
through Autogen Bio Clear (Wiltshire, UK). The secondary
antibodies were obtained from Dako A/S, Denmark. All other
chemicals were purchased from Sigma-Aldridge (Dorset, UK).
Human ZAG and polyclonal anti-hZAG antibody were gifts from
Dr T Zimmerman, Bayer Corp., Raleigh, NC, USA.
Purification of LMF
Lipid-mobilising factor was purified from the urine of cachectic
cancer patients using a combination of batch extraction on DEAE-
cellulose and hydrophobic interaction chromatography (Todorov
et al, 1998). Particulate material was removed from urine by
centrifugation at 3000 g for 10min, after which it was diluted
with 4 vol 10mM Tris-HCI, pH 8.0. DEAE-cellulose, previously
activated by washing in 100mM Tris-HCI, pH 8.0, for 5min was
added to the diluted urine (10 g l1 of original urine) and the
mixture was stirred for 2 h at 41C. The DEAE-cellulose was
recovered by centrifugation (300 g, 10min) and the LMF was
eluted with 0.5 M NaCl in 10mM Tris-HCl, pH 8.0. The eluate was
equilibrated against PBS and concentrated to 1ml by ultrafiltration
in an Amicon filtration cell (Millipore (UK) Ltd, Watford, Herts,
UK) containing a membrane filtre with a molecular weight cutoff
of 10 kDa. Further purification was achieved using a Resource-Iso
HPLC column (Pharmacia Biotech, St Albans, Herts, UK) with a
decreasing (NH4)2SO4 concentration from 1.5 M. Active fractions
containing LMF eluted at 0.6 M (NH4)2SO4 and a sodium
dodecylsulphate polyacrylamide (SDS–PAGE) gel showing the
purity of the product is shown in Figure 1. The LMF was present as
a single band and immunoblotting showed it to be cross-reactive
with human ZAG (Figure 2). The upper band is albumin, which co-
purifies with LMF to a small extent. The LMF was desalted before
use by washing five times against PBS using an Amicon fitter.
Zinc-a2-glycoprotein was kindly provided by Dr Tom Zimmer-
man, Bayer Corporation, USA, and was purified from Cohn
Fraction V of human serum.
Cell lines
MAC13 is a colon adenocarcinoma induced in mice by prolonged
administration of 1, 2-dimethylhydrazine (Cowen et al, 1980). Cells
were derived from the solid tumour and maintained in vitro in
RPMI-1640 medium supplemented with 10% FCS at 371C under an
atmosphere of 5% carbon dioxide in air. For cell-growth assays,
cells were taken from semiconfluent cultures and seeded at
1.6 104 cells per well in six-well multiwell dishes (Nunc A/S
Denmark) and left for 2 h before drug addition. Bleomycin, 1, 10-
dimethyl-4,40-bipyridinium dichloride (paraquat), hydrogen per-
oxide or chlorambucil were then added to the cells at the
concentrations shown in the figure legends in the absence or
presence of 0.58 mM LMF for 2 h, following which the experimental
medium was discarded and replaced by fresh medium. Cell
numbers were determined 96 h after drug addition using a Coulter
Counter, model Z1.
Western blot analysis
MAC13 cells were washed with ice-cold PBS, scraped from the
substratum into 100mM HEPES, pH 7.5, 10% sucrose, 0.1% NP40,
10mM dithiothreitol and protease inhibitor cocktail (Roche
Diagnostics, Germany), and sonicated at 41C three times for 10 s,
with intervals between each pulse. The protein concentration of the
sample was determined using the Bradford assay using bovine
serum albumin as a standard. Samples of protein (5 mg in 10 ml)
were resolved on 12% SDS–PAGE run at 180V for about 45min
and transferred in a Tris-glycine SDS buffer, to 0.45 mm
nitrocellulose membranes (Hybond A, Amersham, UK), which
had been blocked with 5% Marvel in Tris-buffered saline, pH 7.5,
at 41C overnight. Both anti-UCP-2 and anti-ZAG were used at a
dilution of 1 : 1000, while the secondary antibodies were peroxidase
conjugated, either goat anti-rabbit or rabbit anti-mouse used at a
dilution of 1 : 2000. Incubation was for 1 h at room temperature
and development was by enhanced chemiluminescence (ECL)
(Amersham Biosciences, Bucks, UK). Blots were scanned by a
densitometer to quantitate the differences and analysed using
‘Phoretix ID Advanced’ software. Gels were stained with Ponceau S
to confirm equal loading.
Malondialdehyde (MDA) determination
Cells were homogenised in the presence of 5mM butylated
hydroxytoluene to prevent sample oxidation. Cell homogenate
(0.2ml) or 1,1,3,3-tetramethoxypropan (0.2ml, standard) or water
(0.2ml, blank) were added to N-methyl-2-phenylindole (0.2ml)
and the mixture was vortexed prior to adding 12 N HCl (46 ml) and
again mixing well. The tubes were sealed and the samples
incubated at 451C for 60min, followed by centrifugation at
15 000 g for 10min. The clear supernatant was transferred to a
microtitre plate and the absorbance was measured at 570 nm using
an ELISA plate reader (Athos Labtech, Sussex, UK).
Statistical analysis
Results were expressed as mean7s.e.m. Differences were deter-
mined by one-way ANOVA followed by Tukey–Kramer multiple-
comparison test.
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Figure 1 SDS–PAGE of LMF purified from human urine according to
the protocol described in Materials and methods. Lane 1, MW markers;
lane 2, LMF. Detection was by Coomassie brilliant blue stain.
1
43 kDa
2 3 4 5 6
Figure 2 Immunoblot of hZAG (lanes 1–3) and hLMF (lanes 4–6)
(10 mg) detected with polyclonal antibody to hZAG.
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RESULTS
Previous studies (Todorov et al, 1998) have shown LMF to be
homologous to ZAG and using quantitative RT–PCR have found
MAC16, which induces cachexia in vivo, to express high levels of
ZAG mRNA, while MAC13, which does not induce cachexia,
showed no expression of ZAG mRNA. Immunoblotting of soluble
extracts of the two cell lines confirmed no expression of ZAG
protein by MAC13, but high-level expression by MAC16 (Figure 3).
To determine the effect of LMF/ZAG on the expression of UCP-2,
MAC13 cells were treated with various concentrations of LMF for
24 h and the expression of UCP-2 was determined by Western
blotting. Uncoupling protein-2 appears as a doublet (Figure 4),
possibly because it acts as a dimer forming a proton channel in the
mitochondrial inner membrane. As shown in Figure 4A, LMF
produced a concentration-dependent increase in UCP-2, which
was attenuated by co-incubation with the selective b3-adrenor-
eceptor (AR) antagonist SR59230A (Figure 4C). This suggests that
the action of LMF was mediated through interaction with a b3-AR.
ZAG produced a similar effect and appeared to be interchangeable
with LMF and was used in some experiments. The concentrations
of LMF inducing an increase in UCP-2 expression were the same as
those previously found to induce lipolysis in murine epididymal
adipocytes (Hirai et al, 1998). Since maximal induction of UCP-2
expression was observed with 0.58 mM LMF, this concentration was
chosen for further studies. There was no effect of LMF at this
concentration on the growth of MAC13 cells, nor of SR59230A at
10mM.
The effect of bleomycin on growth of MAC13 is shown in
Figure 5. There was a significant reversal of growth inhibition by
bleomycin at all concentrations when cells were co-incubated with
ZAG (0.58 mM), and this growth-enhancing effect was completely
attenuated in the presence of SR59230A, suggesting that the
protective effect of ZAG was mediated through b3-AR and thus
UCP-2 (Figure 5). A similar protective effect was seen by ZAG on
the growth-inhibitory effect of hydrogen peroxide (Figure 6),
although the protective effect decreased as the concentration of
hydrogen peroxide increased and was not apparent in the presence
43 kDa
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Figure 3 Immunoblot of soluble extracts of MAC13 (lanes 1–3) and
MAC16 (lanes 4–6) detected with monoclonal antibody to human ZAG.
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Figure 4 Immunoblot of UCP-2 expression in MAC13 cell line (A) in
the presence of 0 (lane 1), 0.23 (lane 2), 0.35 (lane 3) and 0.58 (lane 4)mM
LMF after 24 h incubation and (B) in the presence of 0 (lanes 1 and 6), 0.23
(lanes 2 and 7), 0.35 (lanes 3 and 8), 0.46 (lanes 4 and 9) and 0.58 (lanes 5
and 10) mM LMF for 24 h in the absence (lanes 1–5) or presence (lanes 6–
10) of 10mM SR59230A. (C) Densitometric analysis of the blot shown in
(B). The symbols ~ are in the absence of SR59230A and ’ in the
presence; n¼ 3. Differences from values in the presence of SR59230A are
indicated as b, Po0.01.
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Figure 5 Effect of bleomycin alone on the growth of MAC13 cells (open
boxes), or in the presence of 0.58mM LMF (hatched boxes), or 0.58mM
LMFþ 10mM SR59230A (stippled boxes). Zinc-a2-glycoprotein alone was
used at a concentration of 0.58mM. Total repeats n¼ 3. Differences from
values in the presence of bleomycin alone are indicated as c, Po0.001,
white differences from bleomycin þZAG are indicated as b, Po0.01, and
d, Po0.001.
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Figure 6 Effect of hydrogen peroxide on the growth of MAC13 cells
alone (open boxes) and in the presence of 0.58 mM ZAG (hatched boxes).
Zinc-a2-glycoprotein alone was used at a concentration of 0.58 mM. Total
repeats n¼ 3. Differences from values in the presence of hydrogen
peroxide alone are indicated as a, Po0.05, and b, Po0.01.
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of 200 mM hydrogen peroxide. Another free-radical generator is
paraquat, which promotes a flux of O2 within cells by
transferring single electrons catalytically from biological reduc-
tants and is toxic to cells (Haly, 1979). Paraquat produced a dose-
dependent decrease in proliferation of MAC16 cells, which was
effectively attenuated in the presence of LMF (Figure 7A). There
was a significant increase of MDA, a recognised marker of
oxidative stress, in the presence of paraquat, and this was
significantly attenuated in the presence of 0.58 mM ZAG
(Figure 7B). The suppressive effect of ZAG on MDA production
in the presence of paraquat was reversed by SR59230A, confirming
that the action of ZAG was mediated through the b3-AR. In
contrast to the action of agents inducing oxidative stress,
chlorambucil, an alkylating agent which inhibits cellular prolifera-
tion by cross-linking DNA (Harrap and Gascoigne, 1976), inhibited
the growth of MAC13 cells (Figure 8), but this growth inhibition
was not attenuated by LMF.
DISCUSSION
Weight loss is a common feature in patients with gastrointestinal
tumours, and is an independent variable of outcome considerably
reducing survival (DeWys, 1985). Weight loss in these patients
decreases the response to chemotherapy, possibly because they
receive lower dose levels because of increased toxicity (Andreyev
et al, 1998). Weight loss is most likely to have an impact on
response when the rate of response is in the 40–80% range
(DeWys, 1985). One potential mechanism for the decreased
response to chemotherapy is that cachectic factors elaborated by
tumours, and producing lipolysis in adipose tissue or protein
degradation in skeletal muscle, may interfere with the action of
anticancer drugs. This study has shown that one such factor, LMF,
has the potential to decrease growth inhibition by agents inducing
free radical damage through an increased expression of UCP-2.
Further support for this suggestion is provided by the high
chemosensitivity of the MAC13 tumour, which does not produce
LMF, and the chemoresistance of the MAC16 tumour, which
secretes LMF (Double and Bibby, 1989). Lipid-mobilising factor is
produced only by cachexia-inducing tumours and is immunolo-
gically identical to ZAG. ZAG is a soluble protein first isolated
from human plasma (Bu¨rgi and Schmid, 1961), the name of which
derives from the tendency to precipitate with zinc salts and its
electrophoretic mobility in the regions of the a2-globulins.
Although ZAG was isolated over 40 years ago, the biological
function remained largely unknown until it was discovered to be
homologous with LMF involved in lipid mobilisation in cancer
cachexia (Hirai et al, 1998). Stimulation of lipolysis by LMF occurs
through a cyclic AMP-dependent process, which appears to be
mediated through a b3-AR (Russell et al, 2002).
Induction of UCP-2 expression in MAC13 cells by LMF was
attenuated by the b3-AR antagonist SR59230A (Nisoli et al, 1996),
suggesting that the b3-AR was involved in the upregulation. Up
regulation of UCP-2 in liver by polyunsaturated fatty acids appears
to involve a prostaglandin/peroxisome-proliferator-activated re-
ceptor a (PPARa)-mediated pathway (Armstrong and Towle,
2001), while thiazolidinediones appear to work through a PPARa
pathway in muscle and adipose tissue (Camirand et al, 1998). In
addition, a cyclic AMP-response element has been found in the
mouse UCP-2 promoter region and increased mRNA for UCP-2
was found in 3T3-L1 adipocytes in the presence of cyclic AMP
analogues (Yoshitomi et al, 1999). In skeletal muscle, catechola-
mines upregulate both UCP-2 and UCP-3 mRNA expression
through direct action on the b2-AR (Nagase et al, 2001). The b3-
AR agonist Tertatol increased UCP-2 expression in white adipose
tissue (Margarets et al, 2001), but this was probably due to fatty
acid release from adipose tissue, since UCP-2 is also regulated by
the fat content on the diet (Fleury et al, 1997). However, the effect
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Figure 7 (A) Effect of paraquat on the growth of MAC13 cells alone
(open boxes) and in the presence of 0.58mM LMF alone (hatched boxes)
or with 10mM SR59230A (stippled boxes). Lipid-mobilising factor was used
alone at a concentration of 0.58mM. Total repeats n¼ 3. Differences from
values in the presence of paraquat alone are indicated as a, Po0.05, and b,
Po0.01, white differences from paraquatþ LMF are indicated as c,
Po0.001. (B) Levels of MDA in MAC13 cells after no treatment (C) or
treatment with 0.1mM paraquat (P), 0.1 mM paraquatþ 0.58 mM ZAG
(PþZAG) or 0.1mM paraquatþ 0.58 mM ZAGþ 10 mM SR59230A
(PþZAGþ SR); n¼ 6. Differences from control are shown as a,
Po0.05, while differences from 0.1mM paraquat are shown as b,
Po0.001, and differences from PþZAG are shown as c, Po0.001.
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Figure 8 Effect of chlorambucil on the growth of MAC13 cells alone
(open boxes) and in the presence of 0.58mM LMF (hatched boxes). Lipid-
mobilising factor was used alone at a concentration of 0.58mM. There were
no significant differences between the two groups.
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of LMF was exerted on MAC13 tumour cells in the absence of fatty
acids, suggesting a direct effect through the b3-AR. The mechan-
ism of this effect is not known, but most likely involves a cyclic
AMP-mediated process.
If UCP-2 is involved in the reduction of free radical formation
(Ricquier and Bouillaud, 2000), then it was predicted that it would
antagonise, the antiproliferative effects of agents acting through a
free radical mechanism. Bleomycin is an antitumour antibiotic
which degrades DMA in a process dependent on the chelation of
ferrous ions, which under aerobic conditions leads to the
formation of the hydroxyl radical in a concerted process, which
is thought not to involve free hydroxyl radicals (Favaudon, 1982).
Despite this, LMF attenuated the antiproliferative effect of
bleomycin in a process which possibly involves the b3-AR, since
it was completely reversed in the presence of SR59230A. The
antiproliferative effect of paraquat and hydrogen peroxide was also
antagonised by LMF, but not that of the alkylating agent
chlorambucil. In addition, production of MDA by paraquat, a
recognised marker of oxidative stress, was shown to be
significantly reduced by ZAG, and the ZAG effect was attenuated
by SR59230A, confirming that it arose through the b3-AR. These
results suggest that one reason for the poor response of cachexia-
inducing tumours to chemotherapy may be the increased
expression of UCP-2 and detoxification of free radical-generating
agents by tumour-produced LMF.
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